← Back to Clinical Trials
Recruiting NCT07271927

NCT07271927 Whole-Body Photobiomodulation for Motor and Cognitive Changes in Parkinson's Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07271927
Status Recruiting
Phase
Sponsor Pusan National University Yangsan Hospital
Condition PARKINSON DISEASE (Disorder)
Study Type INTERVENTIONAL
Enrollment 15 participants
Start Date 2025-02-12
Primary Completion 2025-11-30

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Photobiomodulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 15 participants in total. It began in 2025-02-12 with a primary completion date of 2025-11-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to exploratorily evaluate the extent of motor and cognitive changes, as well as the safety, resulting from approximately 10 weeks of whole-body photobiomodulation (PBM) therapy (about three sessions per week, once daily, 20 minutes per session) in patients with Parkinson's disease.

Eligibility Criteria

Inclusion Criteria: * Individuals diagnosed with Parkinson's disease at Hoehn and Yahr stages 1-3 based on medical history and examination * Adults aged 40 years or older * Individuals able to walk independently Exclusion Criteria: * Individuals with severe cognitive impairment (Korean Mini-Mental State Examination \[K-MMSE\] score ≤ 9) making it difficult to understand and perform tasks * Patients with dementia other than Parkinson's disease dementia * Individuals with implanted medical or other electronic devices * Individuals with severe neuropsychiatric disorders * Individuals treated for alcohol dependence within 6 months prior to screening * Individuals with a history of suicide attempts * Individuals with a history of seizures * Individuals experiencing dyspnea while sitting at rest * Individuals with visual impairment preventing them from reading ordinary text even with corrective lenses * Individuals with hearing impairment preventing them from understanding conversation even with a hearing aid * Individuals who have participated in two or more clinical trials in the same year or in another clinical trial within the past 6 months * Women and men of childbearing potential who are planning pregnancy during the trial or who do not agree to use appropriate contraceptive methods * Pregnant or breastfeeding women * Individuals deemed medically inappropriate for participation by the principal investigator or study staff based on clinically significant findings not otherwise specified above

Contact & Investigator

Central Contact

Jisoo Baik

✉ zisoo@pusan.ac.kr

📞 082+055-360-4159

Frequently Asked Questions

Who can join the NCT07271927 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, studying PARKINSON DISEASE (Disorder). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07271927 currently recruiting?

Yes, NCT07271927 is actively recruiting participants. Contact the research team at zisoo@pusan.ac.kr for enrollment information.

Where is the NCT07271927 trial being conducted?

This trial is being conducted at Yangsan, South Korea.

Who is sponsoring the NCT07271927 clinical trial?

NCT07271927 is sponsored by Pusan National University Yangsan Hospital. The trial plans to enroll 15 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology